Chinese scientists develop AI-assisted gastrointestinal cancer diagnosis system



A team of scientists from China's Sun Yat-Sen University Cancer Center has developed an artificial intelligence (AI)-assisted proprietary upper gastrointestinal cancer endoscopic diagnosis system, against the early diagnosis pain points of upper gastrointestinal cancer endoscopy. The system previously completed the identification and learning from endoscopic image data of more than 50,000 patients with upper gastrointestinal cancer and more than 120,000 healthy people, resulting in a 96% cancer diagnosis rate.

Chinese upper gastrointestinal cancer patients account for 50% of the tally worldwide, with 85% diagnosed during the advanced stage. However, the 5-year survival rate of patients with early upper gastrointestinal cancer is over 90%, so early diagnosis is the key to improving treatment efficacy and patient survival. The early diagnosis rate of upper gastrointestinal cancer in mainland China is less than 10%, due to lack of talent and to the non-obvious early endoscopic characterization of upper gastrointestinal cancer, among others. The system is capable of accurate real-time identification of suspicious lesions, intelligent quality endoscopy and automatic acquisition of images, and cloud AI analysis. It has been previously used at institutions such as Jieyang City People's Hospital and Jiangxi Provincial Cancer Hospital, both Class 3A hospitals.

Reference:

Related news
US-based DelMar Pharmaceuticals Inc., (Nasdaq.DMPI) released interim data from a Phase II trial being held in China for VAL-083 (dianhydrogalactitol), a potential first-in-class DNA-targeting agent.
  • 1565841622638
  • China
  • Drug
China-based Guangzhou KingMed Diagnostics Group Co., Ltd, and compatriot telecoms giant Huawei Technologies Co., Ltd, have now successfully launched an artificial intelligence (AI)-assisted pathological screening model for cervical cancer.
Suzhou-based biotech Innovent Biologics Inc., (HKEX.01801) announced first patient dosing in a Phase I clinical trial in China for IBI101, the firm’s recombinant fully human anti-tumor necrosis factor receptor family super member (OX40) monoclonal antibody (mAb).
  • 1550123008410
  • China
  • Drug
China-based biotech CStone Pharmaceuticals is set to put its lead candidate CS1001, a programmed death ligand-1 (PD-L1) inhibitor to the test in two Phase II studies in lymphoma.
  • 1528876154825
  • China
  • Drug
U.S.-based major Bristol-Myers Squibb (BMS) has presented data for its checkpoint inhibitor nivolumab in a Chinese population at this week’s Chinese Society of Clinical Oncology (CSCO) meeting.
  • 1506740782021
  • China
  • Drug
Recent news
Zulema Tomás Gonzáles, head of Peru’s Ministry of Health (MINSA), this week announced that she will pressure President Martín Vizcarra to approve through emergency decrees two draft laws aimed at improving health access.
Bayer Consumer Health opened its first Asia-Pacific R&D center, located in Qidong, Jiangsu, China.
Guillaume Corpart, managing director of hospital statistics firm Global Health Intelligence, said during an interview with the Mexico Health Review that recent changes in Mexico’s public sector are putting pressure on drug and medical supplies providers.
Shenzhen-based Ionova Life Science Co., Ltd announced a successful RMB 126 million (USD 17.8 million) in a Series A financing round, led by Lilly Asia Ventures, with DYEE Capital participating.
Swiss major Novartis and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed a memorandum of understanding (MoU) to cooperate in research and development (R&D) and education projects to combat neglected diseases such as Hansen's disease (HD), Chagas disease, malaria, and sickle cell disease.
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP) is moving to take a sizeable stake in US-headquartered biotech OncoSec Medical Inc. An agreement has been reached for CGP to acquire 44.2% of OncoSec for USD 25 million, subject to shareholder approval, with an option to fully buy out the company within 12 months.
  • 1571120805603
  • China
The Implementation Plan for the “Two Invoices” System in Public Medical Institutions Drug Procurement” was jointly released by several ministries in Shandong, led by the Health Commission bureau, as well as the Development and Reform Commission, the Healthcare Security Administration, and others.
Analytics Snapshot


Analytics Snapshot